GENTA INCORPORATED /DE/
8-K, 1998-12-09
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: MAGAININ PHARMACEUTICALS INC, 4, 1998-12-09
Next: SPATIALIGHT INC, 8-K, 1998-12-09




                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 2054

                                    FORM 8-K

                                 CURRENT REPORT

                       PURSUANT TO SECTION 13 OR 15(d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

       Date of Report (Date of earliest event reported): December 3, 1998

                               GENTA INCORPORATED
             (Exact name of registrant as specified in its charter)

                         Commission file number 0-19635

              Delaware                                33-0326866
  (State or other jurisdiction of          (I.R.S. Employer Identification
   incorporation or organization)                      Number)



                 3550 General Atomics Court, San Diego, CA 92121
                    (Address of principal executive offices)
                                   (Zip Code)


                                 (619) 455-2700
              (Registrant's telephone number, including area code)




<PAGE>



                               GENTA INCORPORATED
                                    FORM 8-K
                                 CURRENT REPORT

                                TABLE OF CONTENTS

Item 5.        Other Events...................................................3

Signature.....................................................................4

                                      - 2 -




<PAGE>



Item 5.        OTHER EVENTS

         In the Form 10-Q for Genta Incorporated,  Inc. (the "Company") filed on
November 16, 1998,  the Company  stated that on October 22, 1998, the Nasdaq had
advised the Company by letter that the Company's  shares of common stock had not
maintained  a minimum  closing bid price of $1.00 and that the Company  would be
provided  ninety  calendar  days from the date of the  letter in which to regain
compliance  with  the  minimum  bid  price  requirement.   Compliance  would  be
demonstrated  with a minimum bid price of $1.00 or greater  for ten  consecutive
trading days (the "10-Day  Requirement") anytime within the next ninety calendar
days  following  the date of the letter.  However,  if the Company was unable to
meet the 10-Day  Requirement on or before the end of the ninety-day period,  the
Company's securities would be subject to delisting.

         On  December  3,  1998,   the  Company's   securities  met  the  10-Day
Requirement.  On  December  7, 1998,  the  Company  was  advised in a  telephone
discussion  with a  representative  of the Nasdaq  that the  Company had met the
10-Day Requirement and that the Company's common stock is now in compliance with
the minimum bid price requirement.

                                      - 3 -


<PAGE>


                                    SIGNATURE

        Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


Date: December 9, 1998


                                 GENTA INCORPORATED


                                 /s/ Kenneth G. Kasses, Ph.D.
                                 ----------------------------
                                 Kenneth G. Kasses, Ph.D.
                                 Chairman of the Board of Directors, President,
                                 Principal Executive Officer and Principal
                                 Financial Officer

                                      - 4 -


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission